List of Excipients in Branded Drug GLEEVEC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	GLEEVEC	imatinib mesylate	0078-0401	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	GLEEVEC	imatinib mesylate	0078-0401	CROSPOVIDONE
Novartis Pharmaceuticals Corporation	GLEEVEC	imatinib mesylate	0078-0401	FERRIC OXIDE RED
Novartis Pharmaceuticals Corporation	GLEEVEC	imatinib mesylate	0078-0401	FERRIC OXIDE YELLOW
Novartis Pharmaceuticals Corporation	GLEEVEC	imatinib mesylate	0078-0401	HYPROMELLOSES

Gleevec Excipient Strategy and Commercial Opportunities for Imatinib

Last updated: August 3, 2026

Gleevec's excipient opportunity is primarily a generic-development and product-differentiation opportunity, not a branded patent-expansion opportunity. The active ingredient, imatinib mesylate, is available through multiple generic suppliers, while the original Gleevec composition and core compound patents have expired or ceased to block ordinary U.S. generic entry. Commercial value now lies in robust high-dose tablet manufacturing, excipient substitution, patient-friendly delivery systems, pediatric formulations, and supply-chain improvements.

What is Gleevec and which dosage forms use excipients?

Gleevec is Novartis's brand of imatinib mesylate, an oral tyrosine kinase inhibitor approved in the United States for chronic myeloid leukemia, gastrointestinal stromal tumors, and other malignancies with defined molecular drivers. The FDA first approved Gleevec in 2001.[1]

The principal U.S. dosage forms are film-coated tablets:

Product	Strength	Typical commercial role
Gleevec tablets	100 mg	Dose titration, lower daily doses, pediatric and combination dosing
Gleevec tablets	400 mg	High-dose adult treatment and once-daily regimens

The 100 mg and 400 mg tablets contain the same active pharmaceutical ingredient but differ in tablet size, dose loading, and manufacturing requirements. The 400 mg tablet creates the larger excipient and process-development challenge because of its high drug load and the need to maintain hardness, dissolution, content uniformity, and acceptable swallowability.

Gleevec tablets use conventional solid oral excipient classes, including a filler or diluent, disintegrant, lubricant, glidant, binder or film-forming polymer, and coating materials. The FDA product labeling identifies excipients such as microcrystalline cellulose, crospovidone, hypromellose, magnesium stearate, colloidal silicon dioxide, and film-coating components including polyethylene glycol, talc, titanium dioxide, and iron oxides.[2]

What excipients are used in Gleevec tablets?

The Gleevec formulation is a conventional immediate-release film-coated tablet. Its excipient architecture supports high-dose compression and rapid gastrointestinal release rather than controlled release.

Excipient class	Representative Gleevec function	Development objective
Microcrystalline cellulose	Diluent, compressibility aid	Supports tablet strength and manufacturability
Crospovidone	Superdisintegrant	Promotes tablet breakup and dissolution
Magnesium stearate	Lubricant	Reduces ejection force and tooling friction
Colloidal silicon dioxide	Glidant	Improves powder flow and blend uniformity
Hypromellose	Film former or binder function	Supports coating integrity and tablet appearance
Polyethylene glycol	Coating plasticizer	Improves coating flexibility
Talc	Coating aid and anti-tacking agent	Supports coating-process performance
Titanium dioxide and iron oxides	Colorants and opacifiers	Provides product identification and light protection

The precise commercial composition may vary by jurisdiction, manufacturer, and generic product. Generic developers must establish that their selected inactive ingredients are acceptable for the route, dosage form, strength, and patient population. The FDA's Inactive Ingredient Database is a central screening tool, but database precedent does not replace product-specific safety, quality, and regulatory evaluation.[3]

Why is the 400 mg tablet technically important?

A 400 mg imatinib tablet has a high active load relative to total tablet mass. This creates several formulation risks:

• Poor powder flow and blend segregation.
• High compression-force requirements.
• Capping, lamination, or edge chipping.
• Slow disintegration caused by excessive compression.
• Lubricant overmixing and dissolution retardation.
• Large tablet dimensions that affect patient adherence.
• Batch-to-batch variability in dissolution.

The most commercially attractive excipient strategy is therefore not simple substitution. It is a controlled formulation platform that preserves immediate release while improving process robustness, tablet size, coating durability, and patient usability.

When did Gleevec lose exclusivity and generic entry begin?

Gleevec's U.S. small-molecule exclusivity ended in stages as regulatory exclusivity and patents expired.

Milestone	Approximate date	Commercial impact
FDA approval of Gleevec	2001	Established the reference product
New chemical entity exclusivity period	2006	Prevented early ANDA approval
Original imatinib compound patent protection	2013 to 2015 range, depending on applicable extension and patent	Removed the primary compound barrier
U.S. crystalline imatinib mesylate patent period	Extended protection into the early 2020s	Supported settlement-based generic timing
First U.S. generic launches	2016	Opened broad generic competition
Current market	Mature generic market	Price and supply competition dominate

The U.S. Orange Book historically listed patents covering imatinib mesylate and its crystalline form. The key commercial issue was not an unprotected excipient composition but the patent estate around the active pharmaceutical ingredient and solid-state form.[4]

Novartis reached settlements with generic companies that allowed certain imatinib products to enter before the latest listed patent expiry. Generic entry timing varied by company and market. The result was a staged transition from branded exclusivity to multi-source competition.

What is the Orange Book status of Gleevec?

Gleevec is an FDA-approved reference-listed drug. Its Orange Book history is relevant to ANDA developers because listed patents can trigger Paragraph IV certification, a 30-month stay, and patent litigation under the Hatch-Waxman Act.[4]

The commercial relevance of the Orange Book has declined as the principal Gleevec patents expired and numerous generic imatinib products received approval. New entrants must still review:

• Listed drug patent history.
• Patent delisting or expiry status.
• Reference product exclusivity.
• Approved labeling and dosage strengths.
• Suitability of proposed inactive ingredients.
• Whether the proposed product requires a suitability petition or another regulatory pathway.

For a conventional generic tablet, the normal pathway is an ANDA showing pharmaceutical equivalence and bioequivalence to Gleevec. An excipient change does not automatically convert the product into a 505(b)(2) application. A 505(b)(2) strategy becomes more relevant when the developer changes the dosage form, route, release profile, indication, or clinical use in a way that cannot be supported through the ANDA pathway.

Which companies challenge Gleevec patents?

Generic imatinib development involved major companies including Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Apotex, Dr. Reddy's Laboratories, and other ANDA sponsors. Sun Pharma's U.S. generic imatinib launch was among the most visible market entries following settlement and patent litigation involving Novartis.[5]

The principal patent disputes concerned:

• Imatinib mesylate as a chemical entity.
• The beta crystalline form of imatinib mesylate.
• Patent validity and infringement.
• The timing of generic entry.
• Settlement terms governing launch dates and market restrictions.

Excipient composition was generally not the central litigation issue. A generic manufacturer could use a different inactive-ingredient system if the product met FDA requirements and did not infringe a separately enforceable formulation patent.

What formulation patents protect Gleevec?

The strongest historical protection around Gleevec focused on the active ingredient and solid-state form rather than a differentiated delivery platform. Conventional immediate-release tablet excipients are difficult to protect broadly because individual ingredients such as microcrystalline cellulose, crospovidone, and magnesium stearate are well established in the pharmaceutical industry.

Potentially protectable formulation concepts include:

1. Specific excipient ratios that produce a defined dissolution profile.
2. A smaller tablet with equivalent bioavailability.
3. Taste-masked liquid or dispersible formulations.
4. Pediatric granules or oral suspensions.
5. Modified-release imatinib systems.
6. Stable fixed-dose combinations.
7. Manufacturing controls that produce a defined polymorph or particle-size distribution.
8. Excipient systems that reduce food-effect variability or improve suspension stability.

A company seeking new intellectual-property protection would need a technically differentiated formulation and evidence of a measurable benefit. A patent claiming only a routine substitution of one standard diluent for another would face substantial novelty and obviousness risk.

How strong is the Gleevec patent estate today?

The legacy Gleevec patent estate has limited blocking power against standard U.S. generic imatinib tablets. The commercial market has already shifted to generic competition, and the core compound and crystalline-form disputes no longer provide the protection they once did.

Patent-estate category	Current strategic value
Original imatinib compound claims	Low for new U.S. generic entry because the protection period has ended
Crystalline-form claims	Historical importance; limited current blocking value after generic entry
Method-of-use claims	Potentially relevant only for specific labeled indications or later-added uses
Tablet excipient claims	Limited unless narrowly drafted and technically supported
Pediatric or liquid formulation claims	Potentially valuable for differentiated products
Manufacturing and solid-state control claims	Relevant to API suppliers and complex generic developers
International patents	Country-specific; must be assessed separately

Patent strength also depends on geography. A patent that has expired in the United States may remain relevant in another jurisdiction, while regulatory exclusivity and compulsory licensing rules can differ substantially across emerging markets.

What excipient strategies offer the best commercial opportunity?

1. Generic tablet cost reduction

The largest near-term opportunity is a low-cost, high-throughput immediate-release tablet. Developers can evaluate alternative grades of:

• Microcrystalline cellulose.
• Crospovidone.
• Colloidal silicon dioxide.
• Magnesium stearate.
• Hypromellose coating systems.

The objective is to reduce raw-material cost, shorten blending and compression cycles, and improve yield without changing dissolution or bioequivalence performance.

Supplier qualification is commercially important because imatinib is a chronic-use oncology product. A low-cost excipient that creates supply interruptions, variable lubricant performance, or coating defects can erase price advantages.

2. Smaller and easier-to-swallow tablets

Gleevec's 400 mg strength is relatively large. A formulation that increases drug loading, improves compaction, or uses a more efficient filler system could reduce tablet volume.

Potential technologies include:

• Co-processed excipients.
• Direct-compression platforms.
• Granulation systems that improve density.
• High-functionality binders.
• Optimized particle-size distributions.
• Dual-layer or multilayer tablets.

Any reduction in tablet size must preserve dissolution, content uniformity, mechanical strength, and bioequivalence. The commercial opportunity is strongest where adherence is affected by tablet burden or where patients take multiple oncology medicines.

3. Pediatric formulations

Pediatric treatment creates a clearer unmet-need opportunity than a standard generic tablet. Children may need doses below available tablet strengths or have difficulty swallowing film-coated tablets.

Possible products include:

• Oral suspension.
• Ready-to-use liquid.
• Dispersible tablet.
• Mini-tablet.
• Sachet or granule formulation.
• Unit-dose powder for reconstitution.

Excipient selection must address taste, sedimentation, redispersibility, preservative strategy, dosing accuracy, and chemical stability. Imatinib's bitterness makes taste masking a central development issue. Ion-exchange resins, polymeric coatings, lipid systems, and sweetener-flavor combinations are possible approaches, but each introduces regulatory and stability requirements.

A pediatric formulation can support a 505(b)(2) strategy if it creates a materially different dosage form or clinical use. It may also support formulation patents if the excipient system delivers a demonstrated advantage.

4. Liquid and dispersible products for dysphagia

Adult oncology patients may experience dysphagia, mucositis, nausea, or treatment-related weakness. A dispersible product could expand use among patients who cannot swallow conventional tablets.

The product must control:

• Dose recovery from the container.
• Uniformity after dispersion.
• Contact time between imatinib and oral mucosa.
• Taste and mouthfeel.
• Chemical stability in water or vehicle.
• Compatibility with feeding tubes, if claimed.
• Microbial quality for aqueous products.

A liquid product also creates packaging opportunities, including unit-dose sachets, oral syringes, child-resistant bottles, and single-use reconstitution systems.

5. Sustainable coating and packaging systems

Film-coating systems can reduce solvent use, energy consumption, and manufacturing cycle time. Water-based coating is already standard for many tablets, so the opportunity is incremental rather than disruptive.

Commercially relevant improvements include:

• Lower coating weight.
• Faster drying.
• Reduced colorant complexity.
• Improved light protection.
• Recyclable secondary packaging.
• Blister systems that reduce moisture exposure.

Sustainability claims require measurable lifecycle or material improvements. They do not substitute for dissolution, stability, and packaging validation.

What FDA regulatory requirements apply to a generic Gleevec product?

A conventional generic imatinib tablet generally requires:

• ANDA submission.
• Pharmaceutical equivalence to the reference product.
• Bioequivalence data.
• CMC information.
• Stability data.
• Inactive-ingredient justification.
• Manufacturing-process validation.
• Container-closure qualification.
• Labeling consistent with the reference product, subject to permissible differences.

For a new liquid, dispersible, modified-release, or pediatric product, the regulatory path may differ. A 505(b)(2) application can provide greater flexibility but usually requires more clinical, pharmacokinetic, formulation, or usability evidence than an ANDA.

FDA review will focus on whether excipient changes affect:

• Drug release.
• Absorption.
• Bioavailability.
• Stability.
• Dose uniformity.
• Safety in the intended population.
• Product administration.

The FDA's guidance on ANDA pharmaceutical equivalence and bioequivalence should be read with the current Gleevec labeling, Orange Book listing, and applicable product-specific guidance.[3,4,6]

Is there biosimilar risk for Gleevec?

There is no biosimilar pathway for Gleevec because imatinib is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic substitution, not biosimilar interchangeability.

Competition comes from:

• Authorized or branded generics.
• ANDA-approved imatinib tablets.
• Low-cost international manufacturers.
• Potential specialty formulations.
• Hospital and group-purchasing contracts.
• API and finished-dose suppliers in regulated and emerging markets.

The absence of biosimilar complexity makes conventional generic entry easier than biologic competition, but price erosion and supply reliability become more important.

What licensing deals and commercial partnerships are relevant?

The most relevant partnership models are:

Partnership model	Commercial purpose
API supply agreement	Secures imatinib mesylate quality, capacity, and cost
Excipient supplier partnership	Provides co-processed or high-functionality excipients
Contract development and manufacturing	Accelerates ANDA or 505(b)(2) development
Regional licensing	Expands access in markets with separate patent or registration requirements
Pediatric formulation licensing	Monetizes a differentiated dosage form
Hospital or distributor agreement	Supports supply tenders and oncology-channel access

A generic tablet has limited licensing value unless it offers a cost, supply, or geographic advantage. A pediatric, liquid, dispersible, or modified-release formulation can command stronger licensing interest if it has regulatory exclusivity, patent protection, or demonstrated clinical utility.

What generic launch risks exist for Gleevec?

The main risks are commercial and technical rather than basic patent blocking.

Technical risks

• Failure to match dissolution across pH conditions.
• Excessive sensitivity to lubricant level.
• Tablet capping at high compression force.
• Inadequate coating adhesion.
• Poor blend uniformity at high drug load.
• Instability caused by moisture, light, or polymorphic conversion.
• Inconsistent suspension performance in liquid products.

Regulatory risks

• Unacceptable inactive-ingredient exposure.
• Inadequate justification for pediatric excipients.
• Bioequivalence failure.
• Labeling divergence from the reference product.
• Clinical or pharmacokinetic requirements for a novel dosage form.

Commercial risks

• Severe price erosion.
• Multiple suppliers competing for the same tenders.
• API shortages or quality failures.
• Low switching rates in oncology practices.
• Reimbursement restrictions.
• Distributor inventory destocking after launch.

How does Gleevec compare with other generic oncology opportunities?

Gleevec has a lower patent barrier than many newer oral oncology products but also a more mature and price-sensitive market.

Factor	Gleevec generic	Newer patented oral oncology drug
Patent barrier	Low to moderate, jurisdiction-dependent	Often high
Biosimilar relevance	None	None for most small molecules
ANDA feasibility	Established	Depends on patent and reference-product status
Price competition	High	Initially lower
Formulation opportunity	Pediatric, liquid, swallowability	May include complex release or combination systems
Brand loyalty	Can persist in oncology	Often stronger during exclusivity
Supply-chain value	High	High, but less price-driven before expiry

The best Gleevec opportunity is a differentiated generic or lifecycle product, not an undifferentiated tablet competing solely on price.

What is the commercial outlook for Gleevec excipient innovation?

Revenue exposure is concentrated in three product categories:

1. High-volume generic 100 mg and 400 mg tablets.
2. Pediatric and dysphagia-oriented formulations.
3. Regional products designed for lower-resource markets and tender supply.

Excipient suppliers can capture value by offering validated platforms that reduce development time or manufacturing variability. Finished-dose manufacturers can capture value through regulatory filings, reliable supply, and differentiated dosage forms. Innovators can capture the highest margin through pediatric or dispersible formulations with defensible patents and regulatory exclusivity.

The strongest commercial thesis is a platform that combines high drug loading, smaller tablet size, acceptable dissolution, and lower manufacturing variability. The strongest lifecycle thesis is a stable, taste-masked pediatric or dysphagia formulation.

Key Takeaways

• Gleevec is an immediate-release imatinib mesylate tablet available in 100 mg and 400 mg strengths.
• Its formulation uses conventional excipient classes, including diluent, disintegrant, lubricant, glidant, binder, and film-coating materials.
• Core U.S. exclusivity has ended, and generic competition is established.
• Excipient patents are unlikely to block ordinary generic entry unless they claim a narrow, technically differentiated formulation.
• The 400 mg tablet presents the greatest high-drug-load manufacturing challenge.
• Pediatric, liquid, dispersible, and smaller-tablet products offer the clearest commercial opportunities.
• Gleevec has generic risk, not biosimilar risk.
• API security, excipient qualification, dissolution robustness, and tender pricing are central commercial variables.

FAQs

Can a generic imatinib manufacturer use different excipients from Gleevec?

Yes. A generic manufacturer can use different inactive ingredients if the formulation meets FDA safety, quality, pharmaceutical-equivalence, and bioequivalence requirements.

Is imatinib a good candidate for a pediatric liquid formulation?

Yes. Pediatric dosing flexibility and tablet-swallowing limitations create a credible development opportunity, but bitterness, chemical stability, dose uniformity, and suspension redispersibility require substantial formulation work.

Do Gleevec excipients affect bioequivalence?

They can. Changes in disintegrant level, lubricant concentration, particle size, compression force, or coating can alter dissolution and absorption performance.

Can a new imatinib formulation receive separate patent protection?

Potentially. A formulation may support patent protection if it has a novel excipient system, measurable performance benefit, and non-obvious technical effect. Routine substitution of standard excipients is less likely to support strong claims.

Does Gleevec require a biosimilar application?

No. Imatinib is a small-molecule drug. A conventional competitor normally uses the ANDA pathway, while a materially different dosage form may require a 505(b)(2) application.

References

1. U.S. Food and Drug Administration. (2001). FDA approves Gleevec for chronic myeloid leukemia.
2. Novartis Pharmaceuticals Corporation. (2023). Gleevec (imatinib mesylate) prescribing information. U.S. Food and Drug Administration.
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Court of Appeals for the Federal Circuit. (2017). Novartis AG v. Sun Pharmaceutical Industries, Inc., patent litigation involving imatinib mesylate.
6. U.S. Food and Drug Administration. (2015). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that reference peptide drug products of rDNA origin.